TCGA-CN-5360-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.350
- WNT_BETA_CATENIN_SIGNALING+0.310
- KRAS_SIGNALING_DN+0.250
- KRAS_SIGNALING_UP+0.250
- MYOGENESIS+0.250
- ALLOGRAFT_REJECTION+0.190
- BILE_ACID_METABOLISM+0.190
- IL6_JAK_STAT3_SIGNALING+0.180
- IL2_STAT5_SIGNALING+0.170
- APICAL_SURFACE+0.140
Top 10 suppressed
- MYC_TARGETS_V1-0.650
- MYC_TARGETS_V2-0.610
- OXIDATIVE_PHOSPHORYLATION-0.610
- E2F_TARGETS-0.510
- DNA_REPAIR-0.440
- MTORC1_SIGNALING-0.420
- G2M_CHECKPOINT-0.410
- FATTY_ACID_METABOLISM-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.340
- GLYCOLYSIS-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NJ-A55A-01A-11R-A262-07 | — | cohortA1 | 0.870 |
| 2 | TCGA-97-8172-01A-11R-2287-07 | — | cohortA1 | 0.863 |
| 3 | MNG690 | — | — | 0.860 |
| 4 | TCGA-86-A4P7-01A-11R-A24X-07 | — | cohortA1 | 0.860 |
| 5 | TCGA-91-8497-01A-11R-2403-07 | — | cohortA1 | 0.854 |
| 6 | TCGA-49-AARR-01A-11R-A41B-07 | — | cohortA1 | 0.854 |
| 7 | TCGA-50-8457-01A-11R-2326-07 | — | cohortA1 | 0.854 |
| 8 | SRR29022838 | — | A | 0.851 |
| 9 | TCGA-75-7025-01A-12R-1949-07 | — | cohortA1 | 0.849 |
| 10 | SRR8613762 | — | A | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.050 | Idelalisib | — uncovered |
| COMPLEMENT | 0.040 | Inavolisib | — uncovered |